IN2014DN05011A - - Google Patents

Download PDF

Info

Publication number
IN2014DN05011A
IN2014DN05011A IN5011DEN2014A IN2014DN05011A IN 2014DN05011 A IN2014DN05011 A IN 2014DN05011A IN 5011DEN2014 A IN5011DEN2014 A IN 5011DEN2014A IN 2014DN05011 A IN2014DN05011 A IN 2014DN05011A
Authority
IN
India
Prior art keywords
nmo
diagnosing
materials
methods
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Vanda A Lennon
Thomas J Kryzer
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of IN2014DN05011A publication Critical patent/IN2014DN05011A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
IN5011DEN2014 2003-11-25 2004-11-24 IN2014DN05011A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/723,180 US7101679B2 (en) 2003-11-25 2003-11-25 Marker for neuromyelitis optica
PCT/US2004/039710 WO2005051178A2 (fr) 2003-11-25 2004-11-24 Marqueur pour la neuromyelite optique

Publications (1)

Publication Number Publication Date
IN2014DN05011A true IN2014DN05011A (fr) 2015-07-10

Family

ID=34592190

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5011DEN2014 IN2014DN05011A (fr) 2003-11-25 2004-11-24

Country Status (9)

Country Link
US (5) US7101679B2 (fr)
EP (1) EP1700120B1 (fr)
JP (1) JP4538464B2 (fr)
CN (1) CN1910456B (fr)
AT (1) ATE424560T1 (fr)
DE (1) DE602004019812D1 (fr)
ES (1) ES2320006T3 (fr)
IN (1) IN2014DN05011A (fr)
WO (1) WO2005051178A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101679B2 (en) 2003-11-25 2006-09-05 Mayo Foundation For Medical Education And Research Marker for neuromyelitis optica
US20070093673A1 (en) * 2005-10-24 2007-04-26 Andre Vachereau Boron-containing compounds, uses and preparation thereof
JP4273235B2 (ja) * 2006-06-01 2009-06-03 国立大学法人 新潟大学 アクアポリン４阻害薬
WO2009039363A2 (fr) * 2007-09-20 2009-03-26 Mayo Foundation For Medical Education And Research Autoanticorps de la neuromyélite optique en tant que marqueur d'une néoplasie
JP5117336B2 (ja) * 2008-09-18 2013-01-16 国立大学法人 千葉大学 多発性硬化症またはｎｍｏの検査マーカーの測定方法
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
GR1007341B (el) 2010-04-21 2011-07-05 ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΠΑΣΤΕΡ (κατά ποσοστό 40%), Διαγνωστικος προσδιορισμος
JP2013528799A (ja) 2010-05-13 2013-07-11 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 神経変性疾患の検知および診断のための診断用自己抗体プロファイル
DE102011011280A1 (de) 2011-02-15 2012-08-16 Euroimmun Medizinische Labordiagnostika Ag Diagnosekit sowie ein Verfahren zur Untersuchung einer menschlichen Patientenprobe auf das Vorhandensein von Neuromyelitis-optica-spezifischen Antikörpern
AU2012245205B2 (en) * 2011-04-21 2017-06-01 The Regents Of The University Of California, A California Corporation Compositions and methods for the treatment of neuromyelitis optica
WO2013010003A1 (fr) 2011-07-12 2013-01-17 University Of Medicine And Dentistry Of New Jersey Profils de biomarqueurs diagnostiques pour le dépistage et le diagnostic de la maladie d'alzheimer
AU2012326089A1 (en) * 2011-10-21 2014-05-01 The Board Of Regents Of The University Of Texas System Codon signature for neuromyelitis optica
WO2013147081A1 (fr) * 2012-03-30 2013-10-03 コニカミノルタ株式会社 Procédé de détection d'une matière biologique
WO2013177116A1 (fr) * 2012-05-21 2013-11-28 The Regents Of The University Of California Modification enzymatique d'un auto-anticorps anti-aqp4 pour la modulation de la maladie de devic
CN102898513B (zh) * 2012-10-31 2016-03-16 徐俊 ELISpot视神经脊髓炎诊断试剂盒及其应用
WO2014154907A1 (fr) * 2013-03-28 2014-10-02 Protagen Ag Procédé de diagnostic de la neuromyélite optique
EP3145528A4 (fr) * 2014-05-19 2018-03-14 The Johns Hopkins University Immunisation de peptide à boucle c extracellulaire d'aquaporine-4 extrêmement soluble pour le traitement de neuromyélite optique aiguë
CN106661623A (zh) * 2014-06-30 2017-05-10 西门子医疗有限公司 使用miRNA生物标志物相对于多发性硬化诊断视神经脊髓炎
CN104698190A (zh) * 2015-03-16 2015-06-10 中国人民解放军总医院 用于中枢神经系统脱髓鞘疾病的生物诊断标记物
US10098935B2 (en) * 2015-05-01 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Aquaporin tolerizing vaccines and methods of use thereof
EP3454920B1 (fr) * 2016-05-13 2024-04-24 C. R. Bard, Inc. Cathéter central introduit de manière périphérique destinés à la pédiatrie
CN106318974A (zh) * 2016-08-29 2017-01-11 南方医科大学南方医院 细胞固定工艺及通过该工艺制备aqp4抗体检测试剂盒
KR101977843B1 (ko) 2017-02-16 2019-05-13 국립암센터 시신경척수염 및 다발성경화증의 선별을 위한 바이오마커 및 이의 이용
WO2018190365A1 (fr) * 2017-04-12 2018-10-18 国立大学法人九州大学 Marqueur de douleur neuropathique et son utilisation
KR102089042B1 (ko) * 2017-05-16 2020-03-13 서울대학교병원 보체불활성화법을 이용한 항-아쿠아포린 4 항체의 개선된 검출 방법
CN108998450A (zh) * 2018-08-08 2018-12-14 昆明医科大学第附属医院 引物、cDNA、载体、AQP4单克隆抗体及制备方法
CN110618264A (zh) * 2019-09-10 2019-12-27 南方医科大学 基于量子点聚苯乙烯微球检测抗aqp4抗体的方法
CN111272998A (zh) * 2020-01-09 2020-06-12 天津天海新域生物科技有限公司 一种同时检测中枢脱髓鞘自身抗体aqp4、mog和mbp的方法
CN115232795B (zh) * 2021-07-22 2023-09-19 北京和合医学诊断技术股份有限公司 稳定表达aqp4-m23蛋白的细胞株及其构建方法、应用
CN113358881B (zh) * 2021-08-10 2021-11-30 首都医科大学附属北京天坛医院 用于nmosd预测或复发监测的生物标志物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37273A (en) * 1863-01-06 Improved canteen
US4708713A (en) * 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
US5258503A (en) * 1987-09-08 1993-11-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Autoantibody adsorbent and apparatus for removing autoantibodies using the same
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5214136A (en) * 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5218105A (en) * 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5741671A (en) * 1991-12-12 1998-04-21 The Johns Hopkins University Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1)
US5324638A (en) * 1992-05-13 1994-06-28 Sloan-Kettering Institute For Cancer Research Brain transcription factor, nucleic acids encoding same and uses thereof
DE4227695C1 (de) * 1992-08-21 1993-10-07 Fresenius Ag Zentrifuge zum Auftrennen von Blut in seine Bestandteile
US5676644A (en) 1995-06-07 1997-10-14 Cobe Laboratories, Inc. Extracorporeal blood processing methods and apparatus
WO1997017369A2 (fr) * 1995-11-09 1997-05-15 Trustees Of Boston University Adn comprenant un promoteur de transcription specifique aux neurones et son utilisation dans un vecteur de therapie genique
CA2352167A1 (fr) 1998-11-25 2000-06-08 Amarillo Biosciences, Inc. Regulation positive de l'expression d'aquaporine exercee par un interferon-alpha
US20040014087A1 (en) 1999-06-01 2004-01-22 Incyte Corporation Molecules for diagnostics and therapeutics
US6409726B1 (en) * 1999-11-08 2002-06-25 Alan G. Ellman Electrosurgical instrument for ear surgery
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20040048253A1 (en) 2001-02-21 2004-03-11 Panzer Scott R. Molecules for diagnostics and therapeutics
US7251568B2 (en) 2001-04-18 2007-07-31 Wyeth Methods and compositions for regulating bone and cartilage formation
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20040115629A1 (en) 2002-01-09 2004-06-17 Panzer Scott R Molecules for diagnostics and therapeutics
ATE336808T1 (de) * 2002-06-22 2006-09-15 Spinner Gmbh Elektrotech Koaxialer steckverbinder
US7101679B2 (en) 2003-11-25 2006-09-05 Mayo Foundation For Medical Education And Research Marker for neuromyelitis optica

Also Published As

Publication number Publication date
CN1910456B (zh) 2011-04-13
US7101679B2 (en) 2006-09-05
DE602004019812D1 (de) 2009-04-16
US20120219969A1 (en) 2012-08-30
WO2005051178A2 (fr) 2005-06-09
JP4538464B2 (ja) 2010-09-08
EP1700120A4 (fr) 2007-11-14
CN1910456A (zh) 2007-02-07
EP1700120B1 (fr) 2009-03-04
US8524508B2 (en) 2013-09-03
US20080145870A1 (en) 2008-06-19
ES2320006T3 (es) 2009-05-18
US20140314796A1 (en) 2014-10-23
ATE424560T1 (de) 2009-03-15
US20090143710A1 (en) 2009-06-04
US20050112116A1 (en) 2005-05-26
JP2007518068A (ja) 2007-07-05
WO2005051178A3 (fr) 2005-12-29
US7947254B2 (en) 2011-05-24
EP1700120A2 (fr) 2006-09-13

Similar Documents

Publication Publication Date Title
IN2014DN05011A (fr)
WO2002099054A3 (fr) Hccs comme modificateurs de la voie p53 et methodes d'utilisation associees
MY143215A (en) Multifocal lenses for pre-presbyopic individuals
WO2003066802A3 (fr) Analyse d'expression genique au moyen d'agents de croisement
AU2003284238A1 (en) Indentation hardness test system
SG170793A1 (en) Anti-mn antibodies and methods of using same
WO2001075178A3 (fr) Methodes d'identification d'aptameres peptidiques pouvant alterer un phenotype cellulaire
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
WO2004053497A3 (fr) Procede de prediction de reaction a la therapie dirigee contre le her2
TW200609559A (en) Contact lenses and methods for their design
TW200510398A (en) Novel compounds
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines
WO2004045545A3 (fr) Compositions et procedes destines au traitement du cancer, au criblage des composants anticancereux presumes et a l'estimation de l'evolution du cancer
AU2003223634A1 (en) Peptide deformylase inhibitors
AU2003293556A1 (en) Methods of diagnosing and treating cancer
AU2003285485A1 (en) 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
WO2002061430A3 (fr) Techniques et reactifs destines au traitement des troubles auto-immuns
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2005005456A3 (fr) Inhibiteurs de la peptide deformylase
AU2002258437A1 (en) Peptide deformylase inhibitors
AU2003304490A1 (en) Peptide deformylase inhibitors
AU2003294272A1 (en) Methods for diagnosing the presence or stage of cancer
WO2003099783A3 (fr) Composes de tropane
WO2004036181A3 (fr) Procede de traitement de maladies et de troubles neurologiques